Year: 2017
Type: article
Abstract: As new generations of targeted therapies emerge and tumor genome sequencing discovers increasingly comprehensive mutation repertoires, the functional relationships of mutations to tumor phenotypes remain largely unknown. Here, we measured ex vivo sensitivity of 246 blood cancers to 63 drugs alongside genome, transcriptome, and DNA methylome analysis to understand determinants of drug response. We assembled a primary blood cancer cell encyclopedia data set that revealed disease-specific sensitivities for each cancer. Within chronic lymphocytic leukemia (CLL), responses to 62% of drugs were associated with 2 or more mutations, and linked the B cell receptor (BCR) pathway to trisomy 12, an important driver of CLL. Based on drug responses, the disease could be organized into phenotypic subgroups characterized by exploitable dependencies on BCR, mTOR, or MEK signaling and associated with mutations, gene expression, and DNA methylation. Fourteen percent of CLLs were driven by mTOR signaling in a non-BCR-dependent manner. Multivariate modeling revealed immunoglobulin heavy chain variable gene (IGHV) mutation status and trisomy 12 as the most important modulators of response to kinase inhibitors in CLL. Ex vivo drug responses were associated with outcome. This study overcomes the perception that most mutations do not influence drug response of cancer, and points to an updated approach to understanding tumor biology, with implications for biomarker discovery and cancer care.
DOI: 10.1172/jci93801
Authors: Sascha Dietrich, Małgorzata Oleś, Junyan Lu, Leopold Sellner, Simon Anders, Britta Velten, Bian Wu, Jennifer Hüllein, Michelle da Silva Liberio, Tatjana Walther, Lena Wagner, Sophie Rabe, Sonja Ghidelli-Disse, Marcus Bantscheff, Andrzej K. Oleś, Mikołaj Słabicki, Andreas Mock, Christopher C. Oakes, Shihui Wang, Sina Oppermann, Marina Lukas, Vladislav Kim, Martin Sill, Axel Benner, Anna Jauch, Lesley Ann Sutton, Emma Young, Richard Rosenquist, Xiyang Liu, Alexander Jethwa, Kwang Seok Lee, Joe Lewis, Kerstin Putzker, Christoph Lutz, Davide Rossi, Andriy Mokhir, Thomas Oellerich, Katja Zirlik, Marco Herling, Florence Nguyen-Khac, Christoph Plass, Emma Andersson, Satu Mustjoki, Christof von Kalle, Anthony D. Ho, Manfred Hensel, Jan Dürig, Ingo Ringshausen, Marc Zapatka, Wolfgang Huber, Thorsten Zenz
Institutions: German Cancer Research Center, University Hospital Heidelberg, National Center for Tumor Diseases, European Molecular Biology Laboratory, European Molecular Biology Laboratory, The Ohio State University, Heidelberg University, Karolinska Institutet, Università degli Studi del Piemonte Orientale “Amedeo Avogadro”, Istituto Oncologico della Svizzera Italiana, Friedrich-Alexander-Universität Erlangen-Nürnberg, Goethe University Frankfurt, University of Cambridge, Deutsches Konsortium für Translationale Krebsforschung, University Medical Center Freiburg, University Hospital Cologne, Inserm, Centre de Recherche des Cordeliers, Pitié-Salpêtrière Hospital, Université Pierre-et-Marie-Curie, University of Helsinki, Helsinki University Hospital, Essen University Hospital, University of Zurich
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: hematologic malignancies, chronic lymphocytic leukemia, drug response, drug sensitivity, mutation clusters, B cell receptor signaling, trisomy 12, mTOR signaling, MEK signaling, IGHV mutation, DNA methylation, transcriptome, targeted therapy, kinase inhibitors, disease stratification, prognostic factors
Open Access status: bronze
Funders: Deutsches Krebsforschungszentrum, Hairy Cell Leukemia Foundation, European Molecular Biology Laboratory, Finnish Cancer Institute, Cancer Research UK, European Commission, Bundesministerium für Bildung und Forschung, Cancerfonden, Vetenskapsrådet, Deutsche Krebshilfe, Universitätsspital Zürich, Heidelberger Zentrum für Personalisierte Onkologie Deutsches Krebsforschungszentrum In Der Helmholtz-Gemeinschaft, Medical Research Council, National Cancer Institute
OpenAlex ID: W2771855639
